Get the Stockscreener App
15.02
0.07%
0.0194
Neogenomics Inc stock is traded at $15.02, with a volume of 238.42K.
It is up +0.07% in the last 24 hours and up +10.99% over the past month.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
See More
Previous Close:
$15.04
Open:
$15.08
24h Volume:
238.42K
Relative Volume:
0.36
Market Cap:
$1.93B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-19.51
EPS:
-0.77
Net Cash Flow:
$-29.73M
1W Performance:
-7.95%
1M Performance:
+10.99%
6M Performance:
+1.69%
1Y Performance:
-22.46%
1-Day Range:
$14.96
$15.26
1-Week Range:
$14.96
$16.60
52-Week Range:
$12.77
$21.22
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| NEO | 15.04 | 1.93B | 628.25M | -78.55M | -29.73M | -0.77 |
| TMO | 500.56 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 229.52 | 165.90B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.28 | 36.48B | 6.50B | 1.41B | 1.42B | 3.82 |
| IDXX | 421.62 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
| IQV | 190.55 | 34.31B | 15.32B | 1.41B | 1.96B | 5.95 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
Los Angeles Capital Management LLC Invests $1.10 Million in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
T. Rowe Price Investment Management Reduces Stake in NeoGenomics Inc - GuruFocus.com
Janus Henderson Group PLC's Strategic Reduction in NeoGenomics I - GuruFocus.com
Felicia Williams Joins NeoGenomics Board of Directors - The Bakersfield Californian
NeoGenomics Appoints Former Macy's CFO Felicia Williams to Board of Directors | NEO Stock News - StockTitan
Trend Tracker for (NEO) - Stock Traders Daily
Pathological Examination Market to Grow with Leading Key - openPR
Creative Planning Purchases 7,004 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference - BioSpace
NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.89 Consensus Target Price from Brokerages - Defense World
NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know - MSN
NeoGenomics posts $18M net loss in Q3 - Gulfshore Business
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: NeoGenomics sees growth with NGS and new test launches By Investing.com - Investing.com South Africa
Earnings call: NeoGenomics sees growth with NGS and new test launches - Investing.com India
NeoGenomics' (NEO) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
NeoGenomics Reports Strong Q3 2024 Growth - TipRanks
NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say - MSN
NeoGenomics receives New York state approval for its solid tumor test - MSN
NeoGenomics: Q3 Earnings Snapshot - The Washington Post
NeoGenomics (NASDAQ:NEO) Updates FY 2024 Earnings Guidance - MarketBeat
NeoGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
NeoGenomics Reports Third Quarter 2024 Results - Business Wire
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade - MSN
Emerald Mutual Fund Advisers Trust Sells 314,330 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
Allspring Global Investments Holdings LLC Reduces Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics (NEO) Set to Announce Quarterly Earnings on Tuesday - Defense World
Blue Trust Inc. Boosts Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics gains conditional approval for solid tumour assays in New York - Medical Device Network
NeoGenomics NGS tests gain New York State approval - Investing.com
NEONeoGenomics, Inc. Latest Stock News & Market Updates - StockTitan
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test - Business Wire
Clinical Laboratory Tests Market 2023-2031 | Latest Overview Analysis Report - InsightAce Analytic
Truist Financial Corp Sells 4,699 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
NeoGenomics (NASDAQ:NEO) Shares Down 2.5%Should You Sell? - MarketBeat
Is NeoGenomics (NASDAQ:NEO) A Risky Investment? - Simply Wall St
Neogenomics Inc. (NEO) gets rating Resumed from Craig Hallum - Knox Daily
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 - BioSpace
Analytical Lens: Exploring Neogenomics Inc. (NEO)’s Financial Story Through Ratios - The Dwinnex
Check out these key findings about Neogenomics Inc. (NEO) - SETE News
Renaissance Technologies LLC Cuts Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) - MarketBeat
(NEO) Technical Data - Stock Traders Daily
Breast Cancer Liquid Biopsy Market is expected to Double Its Size - openPR
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
NEO (Neogenomics Inc.) may reap gains as insiders became active recently - Knox Daily
Neogenomics Inc. (NEO)’s results reveal risk - US Post News
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.78%
1.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):